Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hematopoietic Stem Cell Transplantation
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Malignancy
40%
Cell Therapy
40%
Therapeutic Modalities
40%
Antigen-specific
20%
Hematological Malignancies
20%
High Dose
20%
Mantle Cell Lymphoma
20%
Host Cell
20%
Hematopoietic Cell Transplantation
20%
Chemotherapy
20%
Multiple Myeloma
20%
Non-Hodgkin Lymphoma
20%
Follicular Lymphoma
20%
Fully Developed
20%
Disease-associated
20%
Immune Effector Cells
20%
Immunotherapeutics
20%
Ongoing Clinical Trials
20%
Cytotoxic Chemotherapy
20%
Redirection
20%
Long-term Remission
20%
T-product
20%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
20%
Nonspecific Immune Response
20%
MHC-independent
20%
Clinical Decision-making
20%
Immune-mediated
20%
Genetically Engineered
20%
Large B-cell Lymphoma
20%
Lymphoma, B-cell
20%
Allo-hematopoietic Cell Transplantation
20%
Medicine and Dentistry
Hematopoietic Stem Cell Transplantation
100%
Cell Transplantation
100%
Chimeric Antigen Receptor T-Cell Immunotherapy
100%
Hematopoietic Cell
100%
Chimeric Antigen Receptor
42%
Cancer
28%
Cell Therapy
28%
Clinical Trial
14%
Antigen Specificity
14%
Hematologic Malignancy
14%
Mantle Cell Lymphoma
14%
Drug Megadose
14%
Non-Hodgkin Lymphoma
14%
Follicular Lymphoma
14%
Large-Cell Lymphoma
14%
Multiple Myeloma
14%
Effector Cell
14%
Host Cell
14%
Clinical Decision Making
14%
Cytotoxic Chemotherapy
14%
Acute B-Cell Lymphoblastic Leukemia
14%
Major Histocompatibility Antigen
14%
Diseases
14%
Chemotherapy
14%
Immunology and Microbiology
Hematopoietic Cell
100%
Hematopoietic Stem Cell Transplantation
100%
Cell Transplantation
100%
Chimeric Antigen Receptor T-Cell Therapy
100%
Chimeric Antigen Receptor
42%
B Cell
28%
Antigen Specificity
14%
Drug Megadose
14%
Host Cell
14%
Multiple Myeloma
14%
Effector Cell
14%
Lymphoma Cell
14%
Clinical Decision Making
14%
Major Histocompatibility Antigen
14%